Technology area: Biotechnology & Pharmaceuticals
2 pending office actions • 2 art units • 2 examiners • 0 of 2 (0%) have an AI response strategy ready
Selonterra Inc. currently manages 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. This volume of active prosecution suggests a focused engagement with the patent office. The distribution of these matters is spread across 2 distinct examiners, which indicates the portfolio is not concentrated under the review of a single individual.
Furthermore, the portfolio involves 2 distinct art units. This variety in art units suggests that the company's innovations span different technical niches within the broader biotechnology sector. Practitioners should note that the busiest examiner for this portfolio is PERSONS, JENNA L, who is currently handling 1 pending office action.
Having 1 pending action with the busiest examiner means that the workload is distributed among the 2 distinct examiners. This lack of concentration can be beneficial for risk management, as prosecution outcomes are not dependent on the tendencies of a specific examiner. For the practitioner, this requires maintaining familiarity with the specific preferences of PERSONS, JENNA L and the other assigned examiner across the 2 distinct art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 2 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| PERSONS, JENNA L | 1 | 50.8% | +61.7% |
| LU, FRANK WEI MIN | 1 | 62.7% | +67.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17791240 | TREATMENT OF ALZHEIMER'S DISEASE | PERSONS, JENNA L | — |
| 17633667 | USE OF SNCA-MEDIATED GENES FOR DIAGNOSIS AND TREATMENT OF PARKINSON'S DISEASE | LU, FRANK WEI MIN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17791240 | TREATMENT OF ALZHEIMER'S DISEASE | PERSONS, JENNA L | — |
| 17633667 | USE OF SNCA-MEDIATED GENES FOR DIAGNOSIS AND TREATMENT OF PARKINSON'S DISEASE | LU, FRANK WEI MIN | — |
| Art Unit | Apps |
|---|---|
| 1637 | 1 |
| 1683 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 17791240 | TREATMENT OF ALZHEIMER'S DISEASE | PERSONS, JENNA L | 1637 | §103§112 | Non-Final OA | — | Pending | Jul 07, 2022 |
| 17633667 | USE OF SNCA-MEDIATED GENES FOR DIAGNOSIS AND TREATMENT OF PARKINSON'S DISEASE | LU, FRANK WEI MIN | 1683 | §102§112 | Final Rejection | — | Pending | Feb 08, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialSelonterra Inc. has 2 pending office actions as of October 2026, spread across 2 art units and 2 examiners.
Jenna L Persons has the most, with 1 of Selonterra Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
